Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to determine the estimated clinical specificity of the AAD Plus. A secondary objective is to determine the estimated sensitivity of the AAD Plus as 10% of the study subject samples will be contrived to be positive.


Clinical Trial Description

This study is a multi-site trial assessing the clinical specificity of AAD Plus using capillary blood, venous blood, and venous serum samples collected from presumptive anthrax negative subjects who present with symptoms consistent with cold, flu or other bronchial and febrile infections in the US. At least 440 subjects who meet the study eligibility criteria will have 3 blood samples from a single time point tested with the AAD Plus device. The samples will be: 1) capillary blood collected by finger stick; 2) venous blood collected in a sodium citrate anticoagulant tube; and, 3) serum obtained from venous blood collected in a serum separator tube. The capillary blood sample will be tested immediately to avoid clotting by an unblinded staff member. The venous blood and serum samples will be tested by a blinded staff member as soon as possible after preparation. Additional aliquots of the serum sample will be prepared and stored frozen at -20 ± 2°C or colder for possible additional reference testing [CDC reverse-transcriptase polymerase chain reaction (RT-PCR) assay (K140426)] in the event that any of the subject's capillary blood, venous blood, or serum sample is positive. At each clinical site, subjects' paired venous whole blood and serum samples will be randomly selected such that 10% of all subjects' samples (total of 40) will be spiked with recombinant anthrax lethal factor (LF) to prepare a contrived positive sample. Each clinical site will be provided a unique randomization list by the Data Management Center that identifies, which subjects will be randomized for spiking with LF. The numbers of spiked samples will be distributed approximately equally between all sites. An unblinded site staff member will prepare the blinded, spiked (from 40 subjects selected for spiking) and unspiked (from 400 subjects that are not selected for spiking) venous blood and serum specimens to be tested by a blinded staff member. Before the venous blood sample and serum specimens (from subjects selected for spiking) are spiked; the unblinded staff member will also test all unspiked samples on the AAD Plus and record the results. Then the spiked venous blood and serum sample will be given to the blinded staff member for testing. Thus, blinded staff will receive whole blood and serum samples that could be either unspiked (presumed negative) or spiked (presumed positive) to preserve the blind. In the rare event that the AAD Plus test result is positive on the unspiked sample tested by the unblinded staff member, then the unblinded staff member will give the unspiked sample from this subject to the blinded operator for AAD Plus testing and the subject's serum sample will be sent for reference testing as described above. Blinded staff will remain blinded throughout the study to the contrived spiking of the whole blood and serum samples as to which samples were contrived. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04320485
Study type Observational
Source InBios International, Inc.
Contact
Status Completed
Phase
Start date March 25, 2020
Completion date December 17, 2020

See also
  Status Clinical Trial Phase
Completed NCT00114621 - Anthrax Vaccine Clinical Trials Phase 1
Recruiting NCT00050310 - Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
Completed NCT01453907 - Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers Phase 1
Completed NCT01491607 - Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults Phase 3
Completed NCT03518125 - BARDA Securing Anthrax Immunity For the Elderly Phase 2
Completed NCT04660201 - Anthrax AV7909 Liquid vs Lyophilized Phase 1
Recruiting NCT06365073 - A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
Completed NCT03877926 - VELOCITY: An Anthrax Vaccine Clinical Study Phase 3
Completed NCT03498027 - Febrile Whole Blood Specimen Collection and Testing
Terminated NCT00964834 - Ph1 Study of Valortim and Doxycycline in Humans Phase 1
Completed NCT00063843 - Anthrax-rPA: Safety, Tolerability, Immunogenicity Phase 1
Completed NCT01624532 - A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Phase 2
Completed NCT04148118 - A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults Phase 1
Terminated NCT05672875 - Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System
Completed NCT01770743 - A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels Phase 2
Completed NCT00845650 - Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) Phase 1/Phase 2
Completed NCT01867957 - Efficacy and Safety of Anthrax Vaccine, GC1109 Phase 1
Completed NCT00031291 - Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin N/A
Not yet recruiting NCT03569514 - Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
Recruiting NCT05997264 - Anthrax AV7909 Boost Evaluation Study Phase 2